




# V-PLEX<sup>®</sup> Serology Panels for SARS-CoV-2 Variants

V-PLEX Serology Panels now available for more than 35 SARS-CoV-2 variants, including the Alpha, Beta, Gamma, Delta, Lambda, and Mu variants. These tests supplement MSD's V-PLEX SARS-CoV-2 Panel 2, which was chosen by Operation Warp Speed (OWS) as the basis of its standard binding assays for immunogenicity assessments in all funded Phase III clinical trials of vaccines.

Kits are available for use with human and mouse samples. All human V-PLEX Serology Panels are provided as complete kits, including the same reference standards and controls that are being used in OWS laboratories to analyze clinical trial samples. The Reference Standard 1 in human V-PLEX Serology kits is calibrated against the WHO International Standard (NIBSC code: 20/136).


Human kits are available in 96- and 384-well formats for quantitative serological testing and functional testing (ACE2 blocking). Mouse kits are available in 96-well format for qualitative serological testing.



**MSD MULTI-SPOT<sup>®</sup>  
96-Well 10-Spot Plate**



**MSD MULTI-SPOT<sup>®</sup>  
384-Well 4-Spot Plate**



Visit [www.mesoscale.com](http://www.mesoscale.com) to learn more.



## SARS-CoV-2 Spike Antigens

Lineages	Amino Acid Modifications	Common Designation
A.23.1	F157L, V367F, Q613H, P681R	Uganda
A.VOI.V2	D80Y, ΔY144, ΔI210, D215G, Δ246-248, L249M, W258L, R346K, T478R, E484K, H655Y, P681H, Q957H	Tanzania
AY.1	T19R, Δ157/158, K417N, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineage
AY.1	<b>(Alt Seq 1):</b> T19R, T95I, G142D, E156G, Δ157/158, W258L, K417N, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineage
AY.2	T19R, V70F, G142D, Δ157/158, A222V, K417N, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineage
AY.2	<b>(Alt Seq 1):</b> T19R, V70F, G142D, E156G, Δ157/158, A222V, K417N, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineage
AY.12	T19R, Δ156/157, R158G, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineage
B.1	D614G	-
B.1.1.519	T478K, D614G, P681H, T732A	Mexico/Texas BV-2
B.1.1.7	ΔH69-V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H	<b>Alpha</b>
B.1.1.7+E484K	ΔH69-V70, ΔY144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H	U.K.
B.1.258.17	ΔH69-V70, L189F, N439K, D614G, V772I	Europe
B.1.351	L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V	<b>Beta</b>
B.1.351.1	D80A, D215G, K417N, E484K, N501Y, D614G, A701V	Botswana
B.1.429	S13I, W152C, L452R, D614G	<b>Epsilon</b>
B.1.466.2	W152R, N439K, D614G, P681R	Indonesia
B.1.525	Q52R, A67V, ΔH69-V70, ΔY144, E484K, Q677H, D614G, F888L	<b>Eta</b>
B.1.526	L5F, T95I, D253G, E484K, D614G, A701V	<b>Iota</b>
B.1.526.1	D80G, ΔY144, F157S, L452R, D614G, T859N, D950H	New York
B.1.617	L452R, E484Q, D614G	India
B.1.617.1	T95I, G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H	<b>Kappa</b>
B.1.617.2	T19R, Δ157/158, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineage
B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14	<b>(Alt Seq 1):</b> T19R, G142D, Δ156/157, R158G, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineages
B.1.617.2 +1	T19R, G142D, Δ156/157, R158G, L452R, T478K, E484K, D614G, P681R, D950N	<b>Delta</b> +1
B.1.617.2 +2	T19R, G142D, Δ156/157, R158G, L452R, T478K, E484K, N501Y, D614G, P681R, D950N	<b>Delta</b> +2
B.1.617.2 +3	T19R, G142D, Δ156/157, R158G, K417N, L452R, T478K, E484K, N501Y, D614G, P681R, D950N	<b>Delta</b> +3
B.1.617.2 +4	T19R, G142D, Δ156/157, R158G, K417N, N439K, L452R, T478K, E484K, N501Y, D614G, P681R, D950N	<b>Delta</b> +4
B.1.617.2; AY.4	<b>(Alt Seq 2):</b> T19R, T95I, G142D, Δ156/157, R158G, L452R, T478K, D614G, P681R, D950N	<b>Delta</b> sub-lineages
B.1.617.2+ΔY144	T19R, ΔY144, Δ157/158, L452R, T478K, D614G, P681R, D950N	Vietnam
B.1.617.3	T19R, G142D, L452R, E484Q, D614G, P681R, D950N	India
B.1.618	ΔY145/146, E484K, D614G	India
B.1.620	P26S, ΔH69-V70, V126A, ΔY144, Δ242-244, H245Y, S477N, E484K, D614G, P681H, T1027I, D1118H	Europe
B.1.621	T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H, D950N	<b>Mu</b>
BV-1	ΔH69-V70, ΔY144, Q493R, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H	Texas BV-1
C.37	G75V, T76I, ΔR246, ΔS247, ΔY248, ΔL249, ΔT250, ΔP251, ΔG252, D253N, L452Q, F490S, D614G, T859N	<b>Lambda</b>
P.1	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F	<b>Gamma</b>
P.2	E484K, D614G, V1176F	<b>Zeta</b>
P.3	Δ141-143, E484K, N501Y, D614G, P681H, E1092K, H1101Y, V1176F	Philippines
R.1	W152L, E484K, D614G, G769V	Kentucky

- = Not applicable

**Note:** Alternative S-GENE mutations for Spike of AY.1, AY.2, and B.1.617.2 are listed as "Alt Seq #."



## SARS-CoV-2 S1 RBD Antigens

Lineages	Amino Acid Modifications	Common Designation
A.23.1	V367F	Uganda
A.VOI.V2	R346K, T478R, E484K	Tanzania
AY.1	K417N, L452R, T478K	<b>Delta</b> sub-lineage
AY.2	K417N, L452R, T478K	<b>Delta</b> sub-lineage
AY.3	L452R, T478K	<b>Delta</b> sub-lineage
AY.4	L452R, T478K	<b>Delta</b> sub-lineage
AY.5	L452R, T478K	<b>Delta</b> sub-lineage
AY.6	L452R, T478K	<b>Delta</b> sub-lineage
AY.7	L452R, T478K	<b>Delta</b> sub-lineage
AY.12	L452R, T478K	<b>Delta</b> sub-lineage
AY.14	L452R, T478K	<b>Delta</b> sub-lineage
B.1.1.519	T478K	Mexico/Texas BV-2
B.1.1.7	N501Y	<b>Alpha</b>
B.1.1.7+E484K	E484K, N501Y	U.K.
B.1.214.2	Q414K, N450K	Belgium
B.1.258.17	N439K	Europe
B.1.351	K417N, E484K, N501Y	<b>Beta</b>
B.1.351.1	K417N, E484K, N501Y	Botswana
B.1.427	L452R	<b>Epsilon</b>
B.1.429	L452R	<b>Epsilon</b>
B.1.466.2	N439K	Indonesia
B.1.525	E484K	<b>Eta</b>
B.1.526	E484K	<b>Iota</b>
B.1.526.1	L452R	New York
B.1.526.2	S477N	New York
B.1.617	L452R, E484Q	India
B.1.617.1	L452R, E484Q	<b>Kappa</b>
B.1.617.2	L452R, T478K	<b>Delta</b> sub-lineage
B.1.617.2+ΔY144	L452R, T478K	Vietnam
B.1.617.3	L452R, E484Q	India
B.1.618	E484K	India
B.1.620	S477N, E484K	Europe
BV-1	Q493R, N501Y	Texas BV-1
C.37	L452Q, F490S	<b>Lambda</b>
P.1	K417T, E484K, N501Y	<b>Gamma</b>
P.2	E484K	<b>Zeta</b>
P.3	E484K, N501Y	Philippines
R.1	E484K	Kentucky



## SARS-CoV-2 Variant Focus Panels

SARS-CoV-2 384 Panel 2	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K25420U (IgG) K25421U (IgM) K25422U (IgA) K25423U (ACE2)	Spot A1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot A2	A (WT)	SARS-CoV-2 Nucleocapsid	Wuhan
	Spot B1	B.1.351	SARS-CoV-2 S1 RBD (B.1.351)	<b>Beta</b>
	Spot B2	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>

SARS-CoV-2 Panel 5	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15429U (IgG) K15430U (IgM) K15431U (IgA) K15432U (ACE2) <b>Mouse</b> K15478U (IgG) K15479U (IgM) K15480U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	-	<i>BSA</i>	-
	Spot 3	A (WT)	SARS-CoV-2 Nucleocapsid	Wuhan
	Spot 4	-	<i>BSA</i>	-
	Spot 5	-	<i>BSA</i>	-
	Spot 6	-	<i>BSA</i>	-
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	B.1.1.7	SARS-CoV-2 Spike (B.1.1.7)	<b>Alpha</b>
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	-	<i>BSA</i>	-

SARS-CoV-2 Panel 6	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15433U (IgG) K15434U (IgM) K15435U (IgA) K15436U (ACE2) <b>Mouse</b> K15481U (IgG) K15482U (IgM) K15483U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	B.1	SARS-CoV-2 Spike (D614G)	-
	Spot 3	A (WT)	SARS-CoV-2 Nucleocapsid	Wuhan
	Spot 4	-	<i>BSA</i>	-
	Spot 5	-	<i>BSA</i>	-
	Spot 6	-	<i>BSA</i>	-
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	B.1.1.7	SARS-CoV-2 Spike (B.1.1.7)	<b>Alpha</b>
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan



SARS-CoV-2 Panel 7	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15437U (IgG) K15438U (IgM) K15439U (IgA) K15440U (ACE2) <b>Mouse</b> K15484U (IgG) K15485U (IgM) K15486U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	B.1.351	SARS-CoV-2 S1 RBD (B.1.351)	<b>Beta</b>
	Spot 3	A (WT)	SARS-CoV-2 Nucleocapsid	Wuhan
	Spot 4	P.1	SARS-CoV-2 S1 RBD (P.1)	<b>Gamma</b>
	Spot 5	-	<i>BSA</i>	-
	Spot 6	B.1.1.7	SARS-CoV-2 S1 RBD (B.1.1.7)	<b>Alpha</b>
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	B.1.1.7	SARS-CoV-2 Spike (B.1.1.7)	<b>Alpha</b>
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan

SARS-CoV-2 Panel 8	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15444U (IgG) K15445U (IgM) K15446U (IgA) K15447U (ACE2) <b>Mouse</b> K15487U (IgG) K15488U (IgM) K15489U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	B.1.429	SARS-CoV-2 S1 RBD (B.1.429)	<b>Epsilon</b>
	Spot 3	A (WT)	SARS-CoV-2 Nucleocapsid	Wuhan
	Spot 4	B.1.526	SARS-CoV-2 S1 RBD (B.1.526)	<b>Iota</b>
	Spot 5	-	<i>BSA</i>	-
	Spot 6	B.1.526.2	SARS-CoV-2 S1 RBD (B.1.526.2)	New York
	Spot 7	-	<i>BSA</i>	-
	Spot 8	B.1.526	SARS-CoV-2 Spike (B.1.526)	<b>Iota</b>
	Spot 9	B.1.429	SARS-CoV-2 Spike (B.1.429)	<b>Epsilon</b>
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan



**NEW! SARS-CoV-2 Variant Screening Panels**

SARS-CoV-2 Panel 9	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15448U (IgG) K15449U (IgM) K15450U (IgA) K15451U (ACE2) <b>Mouse</b> K15490U (IgG) K15491U (IgM) K15492U (IgA)	Spot 1	B.1.427; B.1.429; B.1.526.1	SARS-CoV-2 S1 RBD (L452R)	<b>Epsilon</b> , California, New York
	Spot 2	B.1.351; B.1.351.1	SARS-CoV-2 S1 RBD (K417N, E484K, N501Y)	<b>Beta</b> , Botswana
	Spot 3	B.1.525; B.1.526; B.1.618; P.2; R.1	SARS-CoV-2 S1 RBD (E484K)	<b>Eta, Iota</b> , India, <b>Zeta</b> , Kentucky
	Spot 4	P.1	SARS-CoV-2 S1 RBD (K417T, E484K, N501Y)	<b>Gamma</b>
	Spot 5	B.1.526.2	SARS-CoV-2 S1 RBD (S477N)	New York
	Spot 6	B.1.1.7	SARS-CoV-2 S1 RBD (N501Y)	<b>Alpha</b>
	Spot 7	B.1.1.7+E484K; P.3	SARS-CoV-2 S1 RBD (E484K, N501Y)	U.K., Philippines
	Spot 8	B.1.617; B.1.617.1; B.1.617.3	SARS-CoV-2 S1 RBD (L452R, E484Q)	<b>Kappa</b> , India
	Spot 9	B.1.214.2	SARS-CoV-2 S1 RBD (Q414K, N450K)	Belgium
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan

SARS-CoV-2 Panel 11	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15455U (IgG) K15456U (IgM) K15457U (IgA) K15458U (ACE2) <b>Mouse</b> K15495U (IgG) K15496U (IgM) K15497U (IgA)	Spot 1	B.1.427; B.1.429; B.1.526.1	SARS-CoV-2 S1 RBD (L452R)	<b>Epsilon</b> , California, New York
	Spot 2	B.1.351; B.1.351.1	SARS-CoV-2 S1 RBD (K417N, E484K, N501Y)	<b>Beta</b> , Botswana
	Spot 3	B.1.525; B.1.526; B.1.618; P.2; R.1	SARS-CoV-2 S1 RBD (E484K)	<b>Eta, Iota</b> , India, <b>Zeta</b> , Kentucky
	Spot 4	P.1	SARS-CoV-2 S1 RBD (K417T, E484K, N501Y)	<b>Gamma</b>
	Spot 5	B.1.526.2	SARS-CoV-2 S1 RBD (S477N)	New York
	Spot 6	B.1.1.7	SARS-CoV-2 S1 RBD (N501Y)	<b>Alpha</b>
	Spot 7	B.1.1.7+E484K; P.3	SARS-CoV-2 S1 RBD (E484K, N501Y)	U.K., Philippines
	Spot 8	B.1.617; B.1.617.1; B.1.617.3	SARS-CoV-2 S1 RBD (L452R, E484Q)	<b>Kappa</b> , India
	Spot 9	AY.3; AY.4; AY.5; AY.6; AY.7; AY.12; AY.14; B.1.617.2; B.1.617.2+Δ144	SARS-CoV-2 S1 RBD (L452R, T478K)	<b>Delta</b> sub-lineages, Vietnam
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan



SARS-CoV-2 Panel 12	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15459U (IgG) K15460U (IgM) K15461U (IgA) K15462U (ACE2) <b>Mouse</b> K15503U (IgG) K15504U (IgM) K15505U (IgA)	Spot 1	A.23.1	SARS-CoV-2 S1 RBD (V367F)	Uganda
	Spot 2	C.37	SARS-CoV-2 S1 RBD (L452Q, F490S)	<b>Lambda</b>
	Spot 3	B.1.525; B.1.526; B.1.618; P.2; R.1	SARS-CoV-2 S1 RBD (E484K)	<b>Eta, Iota, India, Zeta,</b> India, Kentucky
	Spot 4	BV-1	SARS-CoV-2 S1 RBD (Q493R, N501Y)	Texas BV-1
	Spot 5	B.1.1.519	SARS-CoV-2 S1 RBD (T478K)	Mexico/Texas BV-2
	Spot 6	A.VOI.V2	SARS-CoV-2 S1 RBD (R346K, T478R, E484K)	Tanzania
	Spot 7	B.1.1.7+E484K; P.3	SARS-CoV-2 S1 RBD (E484K, N501Y)	U.K., Philippines
	Spot 8	B.1.617; B.1.617.1; B.1.617.3	SARS-CoV-2 S1 RBD (L452R, E484Q)	<b>Kappa,</b> India
	Spot 9	AY.3; AY.4; AY.5; AY.6; AY.7; AY.12; AY.14; B.1.617.2; B.1.617.2+Δ144	SARS-CoV-2 S1 RBD (L452R, T478K)	<b>Delta</b> sub-lineages, Vietnam
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan

SARS-CoV-2 Panel 13	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15463U (IgG) K15464U (IgM) K15465U (IgA) K15466U (ACE2) <b>Mouse</b> K15506U (IgG) K15507U (IgM) K15508U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	P.2	SARS-CoV-2 Spike (P.2)	<b>Zeta</b>
	Spot 3	B.1.617.1	SARS-CoV-2 Spike (B.1.617.1)	<b>Kappa</b>
	Spot 4	B.1.617.2	SARS-CoV-2 Spike (B.1.617.2)	<b>Delta</b> sub-lineage
	Spot 5	B.1.617.3	SARS-CoV-2 Spike (B.1.617.3)	India
	Spot 6	B.1.617	SARS-CoV-2 Spike (B.1.617)	India
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	B.1.1.7	SARS-CoV-2 Spike (B.1.1.7)	<b>Alpha</b>
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	B.1.526.1	SARS-CoV-2 Spike (B.1.526.1)	New York

SARS-CoV-2 Panel 14	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15468U (IgG) K15469U (IgM) K15470U (IgA) K15471U (ACE2) <b>Mouse</b> K15509U (IgG) K15510U (IgM) K15511U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	A.23.1	SARS-CoV-2 Spike (A.23.1)	Uganda
	Spot 3	A.VOI.V2	SARS-CoV-2 Spike (A.VOI.V2)	Tanzania
	Spot 4	B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14	SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	<b>Delta</b> sub-lineages
	Spot 5	C.37	SARS-CoV-2 Spike (C.37)	<b>Lambda</b>
	Spot 6	R.1	SARS-CoV-2 Spike (R.1)	Kentucky
	Spot 7	P.3	SARS-CoV-2 Spike (P.3)	Philippines
	Spot 8	B.1.525	SARS-CoV-2 Spike (B.1.525)	<b>Eta</b>
	Spot 9	B.1.1.519	SARS-CoV-2 Spike (B.1.1.519)	Mexico/Texas BV-2
	Spot 10	BV-1	SARS-CoV-2 Spike (BV-1)	Texas BV-1

Note: Alternative S-GENE mutations for Spike of B.1.617.2 are listed as "Alt Seq #."



SARS-CoV-2 Panel 15	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15499U (IgG) K15500U (IgM) K15501U (IgA) K15502U (ACE2) <b>Mouse</b> K15512U (IgG) K15513U (IgM) K15514U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	AY.1	SARS-CoV-2 Spike (AY.1)	<b>Delta</b> sub-lineage
	Spot 3	AY.2	SARS-CoV-2 Spike (AY.2)	<b>Delta</b> sub-lineage
	Spot 4	B.1.617.2+ΔY144	SARS-CoV-2 Spike (B.1.617.2+ΔY144)	Vietnam
	Spot 5	B.1.620	SARS-CoV-2 Spike (B.1.620)	Europe
	Spot 6	B.1.258.17	SARS-CoV-2 Spike (B.1.258.17)	Europe
	Spot 7	B.1.466.2	SARS-CoV-2 Spike (B.1.466.2)	Indonesia
	Spot 8	B.1.1.7+E484K	SARS-CoV-2 Spike (B.1.1.7+E484K)	U.K.
	Spot 9	B.1.351.1	SARS-CoV-2 Spike (B.1.351.1)	Botswana
	Spot 10	B.1.618	SARS-CoV-2 Spike (B.1.618)	India

SARS-CoV-2 Panel 16	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15516U (IgG) K15517U (IgM) K15518U (IgA) K15519U (ACE2) <b>Mouse</b> K15520U (IgG) K15521U (IgM) K15522U (IgA)	Spot 1	AY.1; AY.2	SARS-CoV-2 S1 RBD (K417N, L452R, T478K)	<b>Delta</b> sub-lineages
	Spot 2	B.1.351; B.1.351.1	SARS-CoV-2 S1 RBD (K417N, E484K, N501Y)	<b>Beta</b> , Botswana
	Spot 3	B.1.525; B.1.526; B.1.618; P.2; R.1	SARS-CoV-2 S1 RBD (E484K)	<b>Eta, Iota</b> , India, <b>Zeta</b> , Kentucky
	Spot 4	B.1.620	SARS-CoV-2 S1 RBD (S477N, E484K)	Europe
	Spot 5	-	<i>BSA</i>	-
	Spot 6	-	<i>BSA</i>	-
	Spot 7	B.1.1.7+E484K; P.3	SARS-CoV-2 S1 RBD (E484K, N501Y)	U.K., Philippines
	Spot 8	B.1.258.17; B.1.466.2	SARS-CoV-2 S1 RBD (N439K)	Indonesia
	Spot 9	AY.3; AY.4; AY.5; AY.6; AY.7; AY.12; AY.14; B.1.617.2; B.1.617.2+Δ144	SARS-CoV-2 S1 RBD (L452R, T478K)	<b>Delta</b> sub-lineages, Vietnam
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan

SARS-CoV-2 Panel 17	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15524U (IgG) K15525U (IgM) K15526U (IgA) K15527U (ACE2) <b>Mouse</b> K15528U (IgG) K15529U (IgM) K15530U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	B.1	SARS-CoV-2 Spike (D614G)	-
	Spot 3	A (WT)	SARS-CoV-2 Nucleocapsid	Wuhan
	Spot 4	B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14	SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	<b>Delta</b> sub-lineages
	Spot 5	-	<i>BSA</i>	-
	Spot 6	-	<i>BSA</i>	-
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	B.1.1.7	SARS-CoV-2 Spike (B.1.1.7)	<b>Alpha</b>
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	A (WT)	SARS-CoV-2 S1 RBD	Wuhan

Note: Alternative S-GENE mutations for Spike of B.1.617.2 are listed as "Alt Seq #."



SARS-CoV-2 Panel 18	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15532U (IgG) K15533U (IgM) K15534U (IgA) K15535U (ACE2) <b>Mouse</b> K15536U (IgG) K15537U (IgM) K15538U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	P.2	SARS-CoV-2 Spike (P.2)	<b>Zeta</b>
	Spot 3	B.1.617.1	SARS-CoV-2 Spike (B.1.617.1)	<b>Kappa</b>
	Spot 4	B.1.617.2; AY.4	SARS-CoV-2 Spike (B.1.617.2; AY.4) <b>Alt Seq 2</b>	<b>Delta</b> sub-lineages
	Spot 5	B.1.617.3	SARS-CoV-2 Spike (B.1.617.3)	India
	Spot 6	B.1.617	SARS-CoV-2 Spike (B.1.617)	India
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	B.1.1.7	SARS-CoV-2 Spike (B.1.1.7)	<b>Alpha</b>
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	B.1.526.1	SARS-CoV-2 Spike (B.1.526.1)	New York

Note: Alternative S-GENE mutations for Spike of B.1.617.2 are listed as "Alt Seq #."

SARS-CoV-2 Panel 19	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15540U (IgG) K15541U (IgM) K15542U (IgA) K15543U (ACE2) <b>Mouse</b> K15544U (IgG) K15545U (IgM) K15546U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	B.1.621	SARS-CoV-2 Spike (B.1.621)	<b>Mu</b>
	Spot 3	AY.2	SARS-CoV-2 Spike (AY.2) <b>Alt Seq 1</b>	<b>Delta</b> sub-lineage
	Spot 4	B.1.617.2; AY.4	SARS-CoV-2 Spike (B.1.617.2; AY.4) <b>Alt Seq 2</b>	<b>Delta</b> sub-lineages
	Spot 5	C.37	SARS-CoV-2 Spike (C.37)	<b>Lambda</b>
	Spot 6	AY.12	SARS-CoV-2 Spike (AY.12)	<b>Delta</b> sub-lineage
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	AY.1	SARS-CoV-2 Spike (AY.1) <b>Alt Seq 1</b>	<b>Delta</b> sub-lineage
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14	SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	<b>Delta</b> sub-lineages

Note: Alternative S-GENE mutations for Spike of AY.1, AY.2, and B.1.617.2 are listed as "Alt Seq #."

SARS-CoV-2 Panel 20	Spot Location	Lineages	Antigens	Common Designation
<b>Human</b> K15551U (IgG) K15552U (IgM) K15553U (IgA) K15554U (ACE2) <b>Mouse</b> K15555U (IgG) K15556U (IgM) K15557U (IgA)	Spot 1	A (WT)	SARS-CoV-2 Spike	Wuhan
	Spot 2	B.1.617.2 +4	SARS-CoV-2 Spike (B.1.617.2 +4)	<b>Delta</b> +4
	Spot 3	B.1.617.2 +3	SARS-CoV-2 Spike (B.1.617.2 +3)	<b>Delta</b> +3
	Spot 4	B.1.617.2; AY.4	SARS-CoV-2 Spike (B.1.617.2; AY.4) <b>Alt Seq 2</b>	<b>Delta</b> sub-lineages
	Spot 5	B.1.617.2 +2	SARS-CoV-2 Spike (B.1.617.2 +2)	<b>Delta</b> +2
	Spot 6	B.1.617.2 +1	SARS-CoV-2 Spike (B.1.617.2 +1)	<b>Delta</b> +1
	Spot 7	P.1	SARS-CoV-2 Spike (P.1)	<b>Gamma</b>
	Spot 8	B.1.1.7	SARS-CoV-2 Spike (B.1.1.7)	<b>Alpha</b>
	Spot 9	B.1.351	SARS-CoV-2 Spike (B.1.351)	<b>Beta</b>
	Spot 10	B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14	SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	<b>Delta</b> sub-lineages

Note: Alternative S-GENE mutations for Spike of B.1.617.2 are listed as "Alt Seq #."

MESO SCALE DISCOVERY, MESO SCALE DIAGNOSTICS, MSD, mesoscale.com, www.mesoscale.com, methodicalmind.com, www.methodicalmind.com, DISCOVERY WORKBENCH, InstrumentLink, MESO, MesoSphere, Methodical Mind, MSD GOLD, MULTI-ARRAY, MULTI-SPOT, QuickPlex, ProductLink, SECTOR, SECTOR PR, SECTOR HTS, SULFO-TAG, TeamLink, TrueSensitivity, TURBO-BOOST, TURBO-TAG, N-PLEX, R-PLEX, S-PLEX, T-PLEX, U-PLEX, V-PLEX, MSD (design), MSD (luminous design), Methodical Mind (design), 96 WELL SMALL-SPOT (design), 96 WELL 1-, 4-, 7-, 9-, & 10-SPOT (designs), 384 WELL 1- & 4-SPOT (designs), N-PLEX (design), R-PLEX (design), S-PLEX (design), T-PLEX (design), U-PLEX (design), V-PLEX (design), It's All About U, SPOT THE DIFFERENCE, The Biomarker Company, and The Methodical Mind Experience are trademarks and/or service marks owned by or licensed to Meso Scale Diagnostics, LLC. All other trademarks and service marks are the property of their respective owners.

©2021 Meso Scale Diagnostics, LLC. All rights reserved.

MK-DS-1082-v5-2021Nov

For Research Use Only. Not for use in diagnostic procedures.